Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours

European Journal of Cancer

Volumn 43, Issue 14, 2007, Pages 2074-2081

  Pein, F ^a   Pinkerton, R ^b   Berthaud, P ^c   Pritchard Jones, K ^d   Dick, G ^d   Vassal, G ^e  

^a Dept de Recherche Therapeutique ^*  (France)

^b Queensland Diabetes Centre   (Australia)

^c NOVARTIS PHARMA AG   (Switzerland)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Ataxia; Childhood cancer; Multi drug resistance; Phase 1; PSC 833; Solid tumours

Indexed keywords

ETOPOSIDE; VALSPODAR;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALOPECIA; ARTICLE; ATAXIA; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG SAFETY; EWING SARCOMA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LOADING DRUG DOSE; MALE; MONOTHERAPY; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; NEUROTOXICITY; NEUTROPENIA; PAIN; PRIORITY JOURNAL; RELAPSE; RHABDOMYOSARCOMA; SEPSIS; SOLID TUMOR; THROMBOCYTOPENIA; TOXICITY; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC AGENTS; ATAXIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEASIBILITY STUDIES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL;

EID: 34548472434     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.07.003     Document Type: Article

References (28)

1. Pinkerton C.R. Multidrug resistance reversal in childhood malignancies - potential for a real step forward?. Eur J Cancer 32 (1996) 161-167
2. Cowie F.J., Pritchard-Jones K., Renshaw J., and Pinkerton C.R. Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines. Int J Oncol 12 (1998) 1143-1149
3. Cocker H.A., Pinkerton C.R., and Kelland L.R. Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines. Br J Cancer 83 (2000) 338-345
4. Cagliero E., Ferracini R., Morello E., et al. Reversal of multi-drug resistance using Valspodar (PSC-833) and doxorubicin in osteosarcoma. Oncol Rep 12 (2004) 1023-1031
5. Cairo M.S., Siegel S., Anas N., and Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine and continuous infusion VP-16 in drug-resistant pediatric tumours. Cancer Res 49 (1989) 1063-1066
6. Theis J.G., Liau Chu M., Chan H.S., Doyle J., Greenberg M.L., and Koren G. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumour resistance: the causative role of improper dissolution of Cremophor EL. J Clin Oncol 13 (1995) 2508-2516
7. Bisogno G., Cowie F., Boddy A., Thomas H.D., Dick G., and Pinkerton C.R. High-dose cyclosporin with etoposide - toxicity and pharmacokinetic interaction in children with solid tumours. Br J Cancer 77 (1998) 2304-2309
8. Boot D.J., Dennis I.F., Twentyman P.R., et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14 (1996) 610-618
9. Kornblau S.M., Estey E., Madden T., et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC 833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15 (1997) 1796-1802
10. Lee E.J., George S.L., Caliguiri M., et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC 833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. J Clin Oncol 17 (1999) 2831-2839
11. Chauncey T.R., Rankin C., Anderson J.E., et al. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide and the MDR modulator PSC 833: a southwest oncology group study 9617. Leuk Res 24 (2000) 567-574
12. Fracasso P.M., Westerveldt P., Fears C.A., et al. Phase I study of paclitaxel in combination with a multidrug resistance modulator PSC 833 (Valspodar), in refractory malignancies. J Clin Oncol 18 (2000) 1124-1134
13. Del Mar Fernandez De Gatta M., Santos-Buelga D., Dominguez-Gill A., et al. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 41 (2002) 115-135
14. Keller R.P., Altermatt H.J., Donatsch P., Zihlmann H., Laissue J.A., and Hiestand P.C. Pharmacologic interactions between the resistance-modifying cyclosporine SCZ PSC 833 and etoposide (VP 16-213) and enhance in vivo cytostatic activity and toxicity. Int J Cancer 51 (1992) 433-438
15. Kornblau S.M., Estey E., Madden T., et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC 833 in relapsed or refractory acute myelogenous leukaemia. J Clin Oncol 15 (1997) 1796-1802
16. Phillips M., Flamant F., Sommelet-Olive D., and Pinkerton C.R. Phase II study of rapid scheduled etoposide in paediatric soft tissue sarcomas. Eur J Cancer 31 5 (1995) 782-784
17. Phillips M.B., and Pinkerton C.R. Pilot study of a rapid etoposide-cisplatin regimen in paediatric soft tissue sarcomas. Eur J Cancer 28 (1992) 399-403
18. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., and Pastan I. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84 (1987) 7735-7738
19. Le Bot M.A., Kernaleguen D., Robert J., Berlion M., and Riche C. Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance. Cancer Chemother Pharmacol 35 (1994) 53-58
20. Gioccone G., Linn S.C., Welink J., et al. A dose finding and pharmacokinetic study of reversal of multidrugf resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumours. Clin Cancer Res 3 (1997) 2005-2015
21. Cowie F., and Pinkerton C.R. Enhanced toxicity of dactinomycin and vincristine by cylosporin given to reverse multidrug resistance. J Clin Oncol 12 (1994) 1988-1999
22. Hu X.F., Slater A., Wall D.M., et al. Rapid up-regulation of MDR1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer 71 (1995) 931-936
23. Hu X.F., Slater A., Rischin D., Kantharidis P., Parkin J.D., and Zalcberg J. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Br J Cancer 79 (1999) 831-837
24. Van der Holt B., Lowenberg B., Burnett A.K., et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukaemia (AML), in relation to MDR1 status at diagnosis. Blood 106 (2005) 2646-2654
25. Greenberg P.L., Lee S.J., Advani R., et al. Mitoxantrone, etoposide and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukaemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22 (2004) 1078-1086
26. Kolitz J.E., George S.L., Dodge R.K., et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukaemia younger then 60 years: final induction results of Cancer and Leukaemia Group B Study 9621. J Clin Oncol 22 (2004) 4290-4301
27. Advani R., Lum B.L., Fisher G.A., et al. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multi-drug resistance. Ann Oncol 16 (2005) 1968-1973
28. Fracasso P.M., Blum K.A., Ma M.K., et al. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br J Cancer 93 (2005) 46-53